Rodman & Renshaw Starts Cancer Genetics, Inc. (CGIX) at Buy

September 26, 2016 7:57 AM EDT
Get Alerts CGIX Hot Sheet
Price: $1.50 +3.45%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade CGIX Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Rodman & Renshaw initiated coverage on Cancer Genetics, Inc. (NASDAQ: CGIX) with a Buy rating and a price target of $6. Analyst Raghuram Selvaraju sees an attractive entry point.

"We are initiating coverage on Cancer Genetics, Inc. (CGI), an emerging molecular diagnostics company focusing primarily on the development and commercialization of high-content precision diagnostics in the oncology sector, with a Buy rating and a 12-month price target of $6.00 per share. In our view, CGI represents a highly differentiated investment opportunity, given its broad pipeline of tests (both commercial-stage and under development), and with its ability to generate high-margin revenue from partnerships with biopharmaceutical firms that are seeking to develop theranostic solutions for patients," said the analyst.

For an analyst ratings summary and ratings history on Cancer Genetics, Inc. click here. For more ratings news on Cancer Genetics, Inc. click here.

Shares of Cancer Genetics, Inc. closed at $1.76 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Rodman & Renshaw

Add Your Comment